Nrf2 overexpression in breast cancer also improves the excess expression of P53 in an inhibitor protein for stimulating apoptosis, also known as Rel-A inhibitor, which promotes cancer development and tumor-associated drug resistance. This evidence concerns the gene TP53 and breast carcinoma.